Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sarepta Therapeutics
Sarepta Therapeutics
Anthem reverses course, agrees to cover Sarepta's Duchenne drug
BioPharma Dive
Mon, 11/13/17 - 08:46 pm
Anthem
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD
Endpoints
Wed, 09/6/17 - 09:52 am
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
golodirsen
New docs spotlight the FDA’s failed attempt to get Sarepta’s flawed Duchenne study retracted
Endpoints
Tue, 08/22/17 - 06:40 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
These 3 Biotechs Just Crushed Analyst Expectations
Motley Fool
Mon, 08/7/17 - 01:36 pm
biotech
earnings
Sarepta Therapeutics
Biogen
Gilead Sciences
BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta
Endpoints
Tue, 07/18/17 - 09:28 am
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Endpoints
Thu, 06/29/17 - 09:10 am
Allergan
Sarepta Therapeutics
Doug Ingram
Sarepta to collaborate with Genethon on DMD gene therapy; Chinese investors pull back on Pluristem investment
Endpoints
Wed, 06/21/17 - 10:57 am
Sarepta Therapeutics
Genethon
Duchenne Muscular Dystrophy
gene therapy
China
Pluristem
After a bruising turn as Sarepta CEO, Chris Garabedian is back in biotech with a new role as godfather to a bunch of startups
Endpoints
Thu, 05/18/17 - 09:46 am
Sarepta Therapeutics
Chris Garabedian
Xontogeny
startups
How Much Would Sarepta Therapeutics Fetch in a Buyout?
Motley Fool
Tue, 05/2/17 - 10:18 am
Sarepta Therapeutics
M&A
Sarepta Therapeutics May Attract Activist Attention
TheStreet.com
Tue, 05/2/17 - 09:55 am
Sarepta Therapeutics
activists
Sarepta CEO Exits Along With a Sanofi Director, So Let's Speculate About a Possible Deal
TheStreet.com
Fri, 04/28/17 - 11:48 am
Sarepta Therapeutics
Sanofi
M&A
Pharma CEOs
Ed Kaye
Biotech Movers: Sarepta, Paratek, PDL BioPharma
TheStreet.com
Mon, 04/24/17 - 10:14 am
Sarepta Therapeutics
Exondys 5
Paratek
omadacycline
PDL Biopharma
patents
Merck
Keytruda
Sarepta chief hands over CMO role to former Regeneron exec
Bizjournals.com
Tue, 04/4/17 - 12:09 am
Sarepta Therapeutics
Regeneron
CMOs
Payor Re-Evaluation On Exondys Positive For Sarepta
Yahoo/Benzinga
Sat, 03/11/17 - 11:59 am
payers
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Sarepta Therapeutics reports 4Q loss
Yahoo/AP
Tue, 02/28/17 - 11:49 pm
Sarepta Therapeutics
earnings
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
Mon, 02/27/17 - 09:15 am
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Sarepta Sells Priority Review Voucher for $125M
Investopedia
Tue, 02/21/17 - 12:23 pm
Sarepta Therapeutics
Gilead Sciences
priority review
FDA
Sarepta eyes a different approach to Duchenne: gene therapy
Bizjournals.com
Wed, 01/11/17 - 09:57 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
gene therapy
WSJ’s editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters
Endpoints
Fri, 12/23/16 - 10:01 am
WSJ
Exondys 51
Duchenne Muscular Dystrophy
Sarepta Therapeutics
For Sarepta, Goldman Adopts 'Wait-And-Watch Approach' On Exondys 51
Yahoo/Benzinga
Wed, 12/21/16 - 10:52 am
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »